N-piperazinyl-3-indolylmethylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-piperazinyl-3-indolylmethylamine
• 英文别名: 3-(4H-piperazin-1-ylmethyl)-1H-indole；3-(piperazin-1-ylmethyl)-1H-indole
• 化学式: C₁₃H₁₇N₃
• mdl: MFCD10698642
• 分子量: 215.298
• InChiKey: ZTNAIHGOFCMOPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  31.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(((2R,3S),2-(2,4-二氟苯基)-3-甲基环氧乙烷-2-基)甲基)-1H-1,2,4-三唑 、 N-piperazinyl-3-indolylmethylamine 在 lithium perchlorate 作用下， 以 乙腈 为溶剂， 生成 (2R,3R)-2-(2,4-difluorophenyl)-3-[4-(1H-indol-3-ylmethyl)piperazin-1-yl]-1-(1,2,4-triazol-1-yl)butan-2-ol
  参考文献：
  名称：

  新型 1-卤代苄基吲哚连接的三唑衍生物作为抗真菌剂的合成和活性

  摘要：

  DOI：

  10.5012/bkcs.2011.32.1.307
• 作为产物：
  描述：

  吲哚 在 三乙酰氧基硼氢化钠 、 溶剂黄146 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 生成 N-piperazinyl-3-indolylmethylamine
  参考文献：
  名称：

  新型 1-卤代苄基吲哚连接的三唑衍生物作为抗真菌剂的合成和活性

  摘要：

  DOI：

  10.5012/bkcs.2011.32.1.307

文献信息

• [EN] N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM<br/>[FR] INDOLES N-ARYLSULFONYL-3-SUBSTITUES PRESENTANT UNE AFFINITE POUR LE RECEPTEUR DE LA SEROTONINE, METHODE DE PREPARATION ET COMPOSITION PHARMACEUTIQUE CONTENANT CES INDOLES
  申请人：SUVEN LIFE SCIENCES LTD

  公开号：WO2004048330A1

  公开（公告）日：2004-06-10

  The present invention relates to novel N-arylsulfonyl-3-substituted indole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their geometric forms, their N-oxides, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel N-arylsulfonyl-3-substituted indoles of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, and pharmaceutically acceptable compositions containing them. This invention also relates to the process for preparing compounds of the general formula (I), pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine. This invention also relates to the novel intermediates involved therein and process of their preparation.

  本发明涉及新型的N-芳基亚磺酰基-3-取代吲哚化合物、其衍生物、类似物、互变异构体、立体异构体、几何异构体、N-氧化物、多晶型、药物可接受的盐、药物可接受的溶剂化物以及含有它们的药物可接受组合物。本发明特别涉及具有通用公式(I)的新型N-芳基亚磺酰基-3-取代吲哚、其衍生物、类似物、互变异构体、立体异构体、多晶型、药物可接受的盐、药物可接受的溶剂化物以及含有它们的药物可接受组合物。本发明还涉及制备通用公式(I)化合物的过程、含有此类化合物的药物组合物以及此类化合物和组合物在医学中的用途。本发明还涉及其中涉及的新中间体及其制备过程。
• Bioactivity-guided synthesis of gramine derivatives as new MT₁ and 5-HT_1A receptors agonists
  作者：Xiu-Juan Yin、Xiao-Yan Huang、Yun-Bao Ma、Chang-An Geng、Tian-Ze Li、Xing-Long Chen、Tong-Hua Yang、Jun Zhou、Xue-Mei Zhang、Ji-Jun Chen

  DOI：10.1080/10286020.2017.1323885

  日期：2017.6.3

  Twenty-four gramine derivatives were synthesized and evaluated on MT1 and 5-HT1A receptors in vitro. Among them, seven derivatives (7, 8, 16, 19, 20, 21, and 24) exhibited higher agonisting activities on MT1 or 5-HT1A receptors. Compared with gramine, derivatives 7, 8, 16, 19, 20, 21, and 24 displayed 1.6–3.5-fold increase in agonistic rates on 5-HT1A receptor. Particularly, derivatives 7, 19, and

  二十四芦竹碱衍生物的合成和评价MT 1和5-HT 1A受体的体外。其中，7个衍生物（7，8，16，19，20，21，和24）表现出对MT更高agonisting活动1或5-HT 1A受体。与芦竹碱，衍生物相比7，8，16，19，20，21，和24显示在激动率1.6-3.5倍的增加对5-HT1A受体。特别地，衍生物7，19，和21上显示出MT显著激动活性1和5-HT 1A受体的EC 50个分别0.51，0.39，0.50毫微米和0.28，0.46，0.23毫微米，的值。总结了草胺衍生物的初步结构-活性关系，以进一步研究MT 1和5-HT 1A受体作为新的潜在激动剂。
• [EN] 2-PHENOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS<br/>[FR] DERIVES DE 2-PHENOXY- ET 2-PHENYLSULFONAMIDE A ACTIVITE ANTAGONISTE DE CCR3 POUR LE TRAITEMENT DE L'ASTHME ET D'AUTRES TROUBLES INFLAMMATOIRES OU IMMUNOLOGIQUES
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004084898A1

  公开（公告）日：2004-10-07

  The present invention relates to a benzenesulfonamide derivative of formula (I), which is useful as an active ingredient of pharmaceutical preparations. The benzenesulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders. In said formula, X represents O or S; R4 represents formulae (a), (b), (c), (d), (e), (f), (g), (h), (i) or (j), the other substituents are as defined in claim 1.

  该发明涉及一种公式(I)的苯磺酰胺衍生物，可用作药物制剂的活性成分。该发明的苯磺酰胺衍生物具有CCR3（CC型趋化因子受体）拮抗活性，可用于预防和治疗与CCR3活性相关的疾病，特别是用于治疗哮喘、特应性皮炎、过敏性鼻炎和其他炎症/免疫性疾病。在上述公式中，X代表O或S；R4代表公式(a)、(b)、(c)、(d)、(e)、(f)、(g)、(h)、(i)或(j)，其他取代基如权利要求书中所定义。
• [EN] SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR<br/>[FR] LIGANDS D'INDOLE SUBSTITUES DESTINES UN RECEPTEUR ORL-1
  申请人：GLAXOSMITHKLINE SPA

  公开号：WO2005005411A1

  公开（公告）日：2005-01-20

  New ligands for the ORL-1 receptor are described, useful for modulating the activity of said receptors in a patient in need thereof, and for preventing and treating illnesses dependent on the stimulation of this receptor. The new compounds conform to structural formula (I), wherein Q is a moiety of formula (II) and R, R0, R1, R2, R3, R4, R5, R6 are further defined in the description.

  描述了用于调节ORL-1受体活性的新配体，适用于需要此类受体的患者，并用于预防和治疗依赖于该受体刺激的疾病。这些新化合物符合结构式（I），其中Q是式（II）的一个部分，而R、R0、R1、R2、R3、R4、R5、R6在描述中进一步定义。
• Substituted indole ligands for the ORL-1 receptor
  申请人：NIKEM RESEARCH S.R.L.

  公开号：EP1676843A1

  公开（公告）日：2006-07-05

  New ligands for the ORL-1 receptor are described, useful for modulating the activity of said receptors in a patient in need thereof, and for preventing and treating illnesses dependent on the stimulation of this receptor. The new compounds conform to structural formula (I) wherein R1, R2, R3, R4 are further defined in the description.

  本文介绍了ORL-1受体的新配体，可用于调节需要该受体活性的患者的活性，并预防和治疗依赖于该受体刺激的疾病。新化合物符合结构式（I），其中R1、R2、R3、R4在描述中进一步定义。